3.23
経口薬物送達の重要な側面である溶解速度は、薬物の粒子サイズに大きく影響されます。ノイエス-ホイットニーの溶解モデルによると、溶解速度は薬物の表面積と直接相関します。表面積が大きいほど、薬物の水への溶解度が高くなり、薬物の溶解速度が速くなります。粒子サイズを小さくすると、有効表面積が増加し、溶解プロセ…
ノイズ・ホイットニー方程式を思い出してください。これは、溶解速度と薬物の表面積との間に直接的な相関関係があることを示唆しています。
固体薬物の表面積は、その粒子サイズに反比例します。
薬物の粒子サイズが小さいと、有効表面積が増加し、薬物と溶媒の相互作用が促進されるため、薬物が急速に溶解します。
グリセオフルビン、ニトロフラントイン、ヒドロコルチゾンなどのステロイドなどの特定の薬物は、水溶性が低いため、経口吸収が不十分です。.
このような薬剤は、粒子サイズを小さくするために微粉化されます。これにより、薬物の表面積が増加し、溶解速度が向上し、経口吸収が上昇する一方で、特定の薬物の投与頻度が減少します。
疎水性薬物の微粉化は、ポリソルベート80のような界面活性剤の添加により、成分間の表面張力を下げることで湿潤性と溶解性を促進することができます。
微粉化は、溶解性に関連するバイオアベイラビリティの問題を解決できないことがあります。そのため、別の技術であるナノサイジングは、ナノメートルサイズの薬物粒子を生成するために使用され、これを経口投与したり、ナノ懸濁液として静脈内注射したりすることができます。
View the full transcript and gain access to JoVE Core videos
Q1: How does the Noyes-Whitney equation relate particle size to drug dissolution?
The Noyes-Whitney equation establishes a direct correlation between dissolution rate and a drug's surface area. Since surface area is inversely related to particle size, smaller particles increase effective surface area and enhance drug-solvent interaction, leading to rapid dissolution. This relationship is fundamental to understanding how particle size modifications improve drug bioavailability.
Q2: Why are poorly soluble drugs like griseofulvin and hydrocortisone micronized?
Drugs with low aqueous solubility, such as griseofulvin, nitrofurantoin, and hydrocortisone, are micronized to reduce particle size and increase effective surface area. This enhancement improves the dissolution rate and elevates oral absorption while potentially decreasing dosing frequency. Micronization is a practical pharmaceutical strategy to overcome solubility-related bioavailability limitations.
Q3: What role do surfactants play in improving hydrophobic drug dissolution?
Surfactants like polysorbate 80 promote wetting and solubility of hydrophobic drugs by lowering surface tension between ingredients. When added to micronized formulations, surfactants enhance drug-solvent interaction and facilitate faster dissolution. This combination of micronization and surfactant addition addresses solubility challenges in poorly water-soluble pharmaceutical compounds.
Q4: When is nanosizing used instead of micronization for drug formulation?
Nanosizing is employed when micronization fails to resolve solubility-related bioavailability issues. This technique produces drug particles in nanometer size, which can be administered orally or injected intravenously as nanosuspensions. Nanosizing enhances dissolution, absorption, and therapeutic effectiveness for difficult-to-deliver drugs that do not respond adequately to conventional micronization.
Q5: What happens to nanosized particles after intravenous administration?
Nanosized particles may aggregate in the bloodstream and be sequestered by the reticuloendothelial system after IV administration, preventing immediate dissolution. However, they eventually dissolve and permeate into the cytoplasm, contributing to systemic drug exposure in a pseudo-extended-release pharmacokinetic profile. This delayed dissolution pattern can provide sustained therapeutic effects.
Q6: How does reducing particle size increase a drug's effective surface area?
A solid drug's surface area is inversely related to its particle size. When particle size decreases, the total surface area available for drug-solvent contact increases proportionally. This larger effective surface area maximizes molecular interactions at the solid-liquid interface, accelerating the dissolution process and improving the rate at which drug molecules enter solution.
Q7: What pharmaceutical parameters can be optimized alongside particle size reduction?
Beyond particle size reduction, excipients such as disintegrants and surfactants can be added to further boost dissolution by promoting tablet disintegration and wetting. These pharmaceutical parameters work synergistically with micronization or nanosizing to overcome solubility barriers. Strategic excipient selection complements particle size modifications to maximize oral bioavailability and therapeutic outcomes.